BIOGNOSYS
11.4.2022 14:02:08 CEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services. The strategic partnership will encompass multiple strategic and commercial initiatives, including NeoGenomics labs offering access to Biognosys proteomics platforms, medical and scientific affairs-joint presentations and discussions, along with joint scientific and technical initiatives.
“At Biognosys, we continuously push the boundaries of what is possible with our proteomics solutions to address key challenges in drug development,” said Kristina Beeler, Ph.D., Chief Business Officer, Biognosys . “Our platforms are transforming research from early drug discovery to clinical biomarker identification. We are excited to now combine our proteomics platforms with NeoGenomics’ immuno-profiling platform to advance our biopharma partners’ oncology drug development programs.”
One of the first efforts of this collaboration saw Biognosys combining its TrueDiscovery™ proteomics platform with NeoGenomics’ MultiOmyx™ multiplexed immunofluorescence (mIF) spatial tissue analysis as a multimodal approach for analyzing the proteins of tumor samples from late-stage melanoma patients treated with immune-checkpoint inhibitors. The dual proteomic and mIF profiling approach allows for a comprehensive characterization of melanoma patients and pinpointed a specific set of biomarkers that may be used to predict a patient’s response to checkpoint inhibitors. The development and utility of this multimodal approach will be presented across two posters by Biognosys and NeoGenomics at the 2022 American Association for Cancer Research (AACR) annual meeting this week. The multimodal offering will also be made available commercially for biopharma partners.
“The need of our pharma customers to access the next state-of-the-art technology to improve diagnostics and clinical trials is top priority for us,” said Gina Wallar, Ph.D., President, Pharma Services, NeoGenomics Laboratories, Inc . “Partnering with Biognosys gives us the added advantage of expanding into proteomics, data analytics and subsequent actionable results, not only in early discovery and translational research but ultimately, in clinical trials impacting patient care.”
AACR Posters
Abstract 3923 : Ubiquitin ligases implicated as predictive biomarkers for poor outcome to immunotherapy in melanoma patients
In this poster presented by Biognosys on April 13, unbiased proteomic profiling with TrueDiscovery was used to characterize melanoma patients and their responses to PD1-targeted immunotherapy. The profiling was able to identify a set of 103 proteomic biomarkers associated with ubiquitination pathways that correlate with treatment outcomes. The results were cross analyzed with the spatial tissue analysis performed via the MultiOmyx platform. These findings need to be further confirmed in orthogonal cohorts, nevertheless the data point to the possibility of more precise targeting of melanoma patients for immunotherapy.
Abstract 1267 : Dual approach using unbiased proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients
Despite clinical advances, durable responses to immune checkpoint inhibitors are not observed in 40-60% of melanoma patients, and current biomarkers do not clearly distinguish responders. In this study presented by NeoGenomics today, a dual proteomic and mIF profiling approach was able to comprehensively characterize melanoma patients and successfully stratify non-responders from responders based on a set of selected protein biomarkers.
To see Biognosys’ full presence at the AACR 2022 annual meeting, please refer to this press release or visit biognosys.com/aacr22 .
About TrueDiscovery™
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio .
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad, Fresno and San Diego, California; Houston, Arizona, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit neogenomics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005058/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global tilføjer Andersen in Indonesia25.6.2026 22:21:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse i Sydøstasien, da VDB Loi in Indonesia skifter navn til Andersen in Indonesia og dermed bliver det nyeste medlemsfirma, der tilslutter sig organisationen. Andersen in Indonesia yder skattemæssig og juridisk rådgivning til multinationale selskaber og udenlandske investorer, der er aktive på det indonesiske marked. Firmaet kombinerer årtiers markedserfaring med en praktisk tilgang, der fokuserer på at levere præcis og individuel rådgivning om komplekse regulatoriske og internationale forhold. "At blive en del af Andersen-brandet afspejler vores engagement i at give kunderne praktisk skattemæssig og juridisk rådgivning af høj kvalitet på grundlag af et bredere internationalt samarbejde," udtalte Tommy Hendharto Oetomo, administrerende partner for Andersen in Indonesia. "Kunder, der driver virksomhed i Indonesien, har brug for stadig mere koordineret støtte på tværs af landegrænser. At blive et medlemsfirma styrker vores evne til at levere den se
I-Pulse Signs Definitive Agreement with the U.S. Department of Commerce for $250 Million CHIPS R&D Award25.6.2026 20:53:00 CEST | Press release
■I-Pulse Will Develop Cutting-Edge Semiconductors that Support American Reindustrialization and National Security Goals■I-Pulse’s Technology Enables Cost-Competitive Development of America’s Vast Untapped Geothermal Energy Resources I-Pulse Co-founders Robert Friedland, CEO, and Laurent Frescaline, CTO, announced today a definitive agreement with the U.S. Department of Commerce’s CHIPS Research and Development Office for a $250 million award for the further development of I-Pulse’s proprietary semiconductor and pulsed power technology. “With today’s announced investment, the Trump administration is strengthening America’s capabilities and enhancing its national and energy security goals,” said Secretary of Commerce, Howard Lutnick. Co-founder Robert Friedland said: “We are excited to partner with the U.S. government to advance our unique, American technology suite to benefit our great nation. This award supports the development of world-leading critical components in the pulsed power t
Burjeel Holdings Prices First MENA Healthcare Sukuk Since 2018, 3.2x Oversubscribed25.6.2026 19:31:00 CEST | Press release
Burjeel Holdings, a leading super-specialty healthcare group in the GCC listed on the Abu Dhabi Securities Exchange, priced its inaugural USD 500 million Regulation S 5-year senior unsecured Sukuk offering due 2031 under its newly established USD 1.5 billion Senior Unsecured Sukuk Programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625449702/en/ Burjeel Holdings’ inaugural Sukuk was priced at a 7.000 % profit rate and a yield of 7.125% (Photo: AETOSWire) The offering attracted significant demand from high-quality international and regional investors, with the orderbook peaking at USD 1.6 billion, representing 3.2x oversubscription. The strength of the orderbook enabled Burjeel to tighten pricing from initial price thoughts in the mid-7% area, with the Sukuk priced at a 7.000% profit rate and a yield of 7.125%, representing the lowest 5-year yield by a GCC-based private non-investment grade corporate issuer since 202
Fossil Fuels Are a Thing of the Past; The Future Is Renewable: The Smarter E Europe Concludes With a Clear Message25.6.2026 19:03:00 CEST | Press release
Packed halls, a vibrant atmosphere and a buzzing vibe – after three days, The smarter E Europe 2026, Europe’s largest alliance of exhibitions for the energy industry, has come to a successful close. The event held at Messe München offered a glimpse of a future-oriented energy world powered by renewables. A strong signal with a clear message went out to the world from the Bavarian capital: The future is renewable. Renewable energies can help ensure a reliable, secure and cost-effective energy supply around the clock, seven days a week. A total of 2,650 exhibitors from 52 countries – many of whom had expanded their booth space compared with the previous year – demonstrated how this can work. More than 66 percent of exhibitors were from outside of Germany. They presented innovative and market-ready products ranging from virtual power plants, smart grid and load control, smart charging solutions, storage technologies and PV hybrid systems to digital platforms transparently and flexibly.The
HeyGen Doubles to $200M ARR in Eight Months on the Rise of Identity-First AI Video25.6.2026 18:02:00 CEST | Press release
HeyGen, the identity-first AI video platform, today announced it has surpassed $200 million in annual recurring revenue, doubling in eight months. The milestone reflects a rapid shift in how individuals, small businesses, and enterprises adopt AI video: as a scalable layer for human communication across languages, formats, and audiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625305891/en/ HeyGen passes $200M in ARR HeyGen's community now spans more than 30 million users in 196 countries and 175+ languages & dialects, from solopreneurs creating professional social videos for the first time to 85% of the Fortune 100 — who together have created more than 118 million videos. That growth has come with rare capital efficiency: HeyGen generates roughly $2.70 in ARR for every dollar of equity capital raised, making it one of the most capital-efficient venture-backed AI companies in the world. "Crossing $200 million in AR
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom